Clever Culture Systems Valuation

Is CC5 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CC5 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CC5's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CC5's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CC5?

Key metric: As CC5 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CC5. This is calculated by dividing CC5's market cap by their current revenue.
What is CC5's PS Ratio?
PS Ratio	23.8x
Sales	AU$1.26m
Market Cap	AU$29.87m

CC5 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	24.5x
Enterprise Value/EBITDA	-6.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does CC5's PS Ratio compare to its peers?

The above table shows the PS ratio for CC5 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2.6x
UBI Universal Biosensors	5.1x	n/a	AU$35.8m
EYE Nova Eye Medical	1.4x	26.3%	AU$33.2m
CMP Compumedics	1x	n/a	AU$47.8m
RHT Resonance Health	3.1x	n/a	AU$26.2m
CC5 Clever Culture Systems	23.8x	n/a	AU$29.9m

Price-To-Sales vs Peers: CC5 is expensive based on its Price-To-Sales Ratio (23.8x) compared to the peer average (2.6x).

Price to Sales Ratio vs Industry

How does CC5's PS Ratio compare vs other companies in the AU Medical Equipment Industry?

9 Companies	Price / Sales	Estimated Growth	Market Cap
SDI SDI	1.2x	5.4%	US$83.19m
SOM SomnoMed	0.9x	9.0%	US$55.32m
CMP Compumedics	1x	n/a	US$30.96m
NXS Next Science	1.1x	30.6%	US$26.50m

9 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: CC5 is expensive based on its Price-To-Sales Ratio (23.8x) compared to the Australian Medical Equipment industry average (4.1x).

Price to Sales Ratio vs Fair Ratio

What is CC5's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CC5 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	23.8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate CC5's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

SDI

AU$131.3m

Engages in the research and development, manufacture, and marketing of dental restorative materials, whitening systems, and other dental materials in Australia, Europe, the United States, and Brazil.

SDI

AU$1.10

2.3%

45.7%

Doctor Care Anywhere Group

AU$24.2m

Provides digital healthcare and development services in the United Kingdom, Australia, and the Republic of Ireland.

DOC

AU$0.064

-1.5%

36.2%

Cogstate

AU$163.7m

A neuroscience technology company, engages in the creation, validation, and commercialization of digital brain health assessments used in both academic and industry sponsored research.

CGS

AU$0.96

-2.0%

-31.9%